| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Division of Pulmonary, Critical Care, and Internal Medicine (Drs. Nadrous and Ryu), Division of Cardiovascular Diseases (Drs. Chaowalit and Pellikka), Department of Health Sciences Research (Mr. Decker), and Pulmonary Hypertension Clinic (Drs. Krowka and Swanson), Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN.
Correspondence to: Jay H. Ryu, MD, FCCP, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: ryu.jay{at}mayo.edu
Study objectives: To determine the impact on survival and clinical correlates of pulmonary hypertension (PH) occurring in patients with idiopathic pulmonary fibrosis (IPF).
Design: Retrospective study.
Setting: Tertiary care, referral medical center.
Patients: Among 487 consecutive patients with IPF, we identified 136 patients who underwent transthoracic echocardiography within 3 months of their initial evaluation at our institution. Patients with left ventricular dysfunction, valvular heart disease, incomplete follow-up, and those in whom pulmonary artery pressures could not be assessed were excluded; the remaining 88 patients were included in this study. Correlations were performed between echocardiographic measures of PH and clinical variables including survival.
Measurements and results: The mean (± SD) estimated systolic pulmonary artery pressure (SPAP) for the 88 patients was 48 ± 16 mm Hg (range, 28 to 116 mm Hg). Among pulmonary function parameters, SPAP correlated best with diffusing capacity of the lung for carbon monoxide (DLCO), to which it was inversely related. For survival analysis, patients were stratified into three groups: 
35 mm Hg (14 patients), 36 to 50 mm Hg (47 patients), and > 50 mm Hg (27 patients). Using the Kaplan-Meier method, the median survival rates for these three groups were 4.8 years, 4.1 years, and 0.7 years, respectively. Those patients with SPAP > 50 mm Hg had significantly worse survival compared to other subgroups (p = 0.009).
Conclusion: In patients with IPF, PH correlates inversely with DLCO and has a significant adverse impact on survival, particularly when SPAP is > 50 mm Hg.
Key Words: echocardiography • idiopathic pulmonary fibrosis • prognosis • pulmonary hypertension
This article has been cited by other articles:
|
|
 |
|
  D. A. Zisman, A. S. Karlamangla, S. M. Kawut, O. A. Shlobin, R. Saggar, D. J. Ross, M. I. Schwarz, J. A. Belperio, A. Ardehali, J. P. Lynch III, et al. Validation of a Method To Screen for Pulmonary Hypertension in Advanced Idiopathic Pulmonary Fibrosis Chest, March 1, 2008; 133(3): 640 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Han, V. V. McLaughlin, G. J. Criner, and F. J. Martinez Pulmonary Diseases and the Heart Circulation, December 18, 2007; 116(25): 2992 - 3005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Taveira-DaSilva, O. M. Hathaway, V. Sachdev, Y. Shizukuda, C. W. Birdsall, and J. Moss Pulmonary Artery Pressure in Lymphangioleiomyomatosis: An Echocardiographic Study Chest, November 1, 2007; 132(5): 1573 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Patel, D. J. Lederer, A. C. Borczuk, and S. M. Kawut Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis Chest, September 1, 2007; 132(3): 998 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Zisman, A. S. Karlamangla, D. J. Ross, M. P. Keane, J. A. Belperio, R. Saggar, J. P. Lynch III, A. Ardehali, and J. Goldin High-Resolution Chest CT Findings Do Not Predict the Presence of Pulmonary Hypertension in Advanced Idiopathic Pulmonary Fibrosis Chest, September 1, 2007; 132(3): 773 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Noth and F. J. Martinez Recent Advances in Idiopathic Pulmonary Fibrosis Chest, August 1, 2007; 132(2): 637 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alakhras, P. A. Decker, H. F. Nadrous, M. Collazo-Clavell, and J. H. Ryu Body Mass Index and Mortality in Patients With Idiopathic Pulmonary Fibrosis Chest, May 1, 2007; 131(5): 1448 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Fell and F. J. Martinez The Impact of Pulmonary Arterial Hypertension on Idiopathic Pulmonary Fibrosis Chest, March 1, 2007; 131(3): 641 - 643. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Nathan, O. A. Shlobin, S. Ahmad, S. Urbanek, and S. D. Barnett Pulmonary Hypertension and Pulmonary Function Testing in Idiopathic Pulmonary Fibrosis Chest, March 1, 2007; 131(3): 657 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hamada, S. Nagai, S. Tanaka, T. Handa, M. Shigematsu, T. Nagao, M. Mishima, M. Kitaichi, and T. Izumi Significance of Pulmonary Arterial Pressure and Diffusion Capacity of the Lung as Prognosticator in Patients With Idiopathic Pulmonary Fibrosis Chest, March 1, 2007; 131(3): 650 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Strange Treatment for Secondary Pulmonary Hypertension Chest, October 1, 2005; 128(4): 1897 - 1898. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
